Novo Nordisk A/S: Share repurchase programme
28 March 2022 - 11:49PM
Novo Nordisk A/S: Share repurchase programme
Bagsværd, Denmark,
28 March
2022 – On 2 February 2022, Novo
Nordisk initiated a share repurchase programme in accordance with
Article 5 of Regulation No 596/2014 of the European Parliament and
Council of 16 April 2014 (MAR) and the Commission Delegated
Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour
Rules"). This programme is part of the overall share repurchase
programme of up to DKK 22 billion to be executed during a 12-month
period beginning 2 February 2022.
Under the programme initiated 2 February 2022, Novo Nordisk will
repurchase B shares for an amount up to DKK 4.4 billion in the
period from 2 February 2022 to 2 May 2022.
Since the announcement 21 March 2022, the following transactions
have been made:
|
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
|
Accumulated, last announcement |
3,524,151 |
|
2,396,381,074 |
| 21 March 2022 |
95,000 |
745.18 |
70,792,042 |
| 22 March 2022 |
101,077 |
740.77 |
74,874,881 |
| 23 March 2022 |
92,000 |
743.05 |
68,360,563 |
| 24 March 2022 |
95,000 |
734.51 |
69,778,138 |
| 25 March 2022 |
105,000 |
724.80 |
76,104,269 |
|
Accumulated under the programme |
4,012,228 |
|
2,756,290,966 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
35,798,396 B shares of DKK 0.20 as treasury shares, corresponding
to 1.5% of the share capital. The total amount of A and B shares in
the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 22 billion during a 12-month period beginning 2 February 2022.
As of 25 March 2022, Novo Nordisk has since 2 February 2022
repurchased a total of 4,012,228 B shares at an average share price
of DKK 686.97 per B share equal to a transaction value of DKK
2,756,290,966.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
| Media: |
|
|
| Ambre Brown
Morley |
+45 3079 9289 |
abmo@novonordisk.com |
| Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
| |
|
|
| Investors: |
|
|
| Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
| Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
| David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
| Jacob Martin
Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
| Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 26 / 2022
- CA220328_Share_repurchase
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Nov 2023 to Nov 2024
